| Literature DB >> 15721755 |
Nikolaj N Ryzhikov1, Nicholas Seneca, Raisa N Krasikova, Natalia A Gomzina, Evgeny Shchukin, Olga S Fedorova, Dmitrij A Vassiliev, Balázs Gulyás, Håkan Hall, Ivanka Savic, Christer Halldin.
Abstract
A straightforward method for the preparation of no-carrier-added (n.c.a.) [18F]flumazenil via standard nucleophilic radiofluorination of the corresponding nitro-analog Ro 15-2344 has been developed. The labeling was performed by employing the K18F/kryptofix complex in DMF at 160 degrees C for 30 min and equimolar ratio [K/K2.2.2]+18F-/precursor. Under these conditions, an 18F incorporation rate into flumazenil was in the range of 55-60%. The final product was isolated by HPLC purification within a total synthesis time of 75 min and a radiochemical yield of about 30% (EOB). Human post-mortem whole-hemisphere autoradiography of brain sections demonstrated selective uptake of the radioligand in the areas of high density of the central benzodiazepine receptors (BZR). PET studies in a cynomolgus monkey and metabolite studies by HPLC demonstrated similar results by [18F]flumazenil as for [11C]flumazenil. In blocking experiments, almost all radioactivity was inhibited by the addition of unlabeled flumazenil. [18F]Flumazenil is a suitable radioligand for PET assessment of the BZR.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15721755 DOI: 10.1016/j.nucmedbio.2004.11.001
Source DB: PubMed Journal: Nucl Med Biol ISSN: 0969-8051 Impact factor: 2.408